China offers experimental Coronavirus vaccine to Aviation workers

▴ china-offers-experimental-coronavirus-vaccine-aviation-workers
China launched the emergency use vaccine program in July, hoping to boost the immunity of groups

 China has offered experimental coronavirus vaccines to aviation industry workers, according to a regulatory notice seen by Reuters, in a push to inoculate high-risk groups to prevent a possible resurgence as economies reopen.

China, which has four COVID-19 vaccines in the final stage of human trials, launched the emergency use vaccine program in July, hoping to boost the immunity of groups such as border inspectors or medical industry workers.

Frontline workers at Chinese airlines, airports, China National Aviation Fuel Group, and TravelSky Technology Limited will be provided a candidate vaccine voluntarily, the notice from China's aviation regulator shows.

The Civil Aviation Administration of China has asked these sectors and firms to compile a list of personal information of employees willing to take the vaccine, the notice adds.

The vaccination is "in response to a possible second wave of infections erupting in the fall and winter, and to the huge pressure facing our work of preventing imported cases as western countries reopen despite the pandemic", according to the notice.

While the regulator did not immediately respond to a Reuters request for comment, several staffers at Air China, China Southern Airlines, and Juneyao Airlines confirmed they had received such a notice.

Juneyao said it had submitted a list of employees willing to take the vaccine. The other airlines did not immediately reply to requests for comments.

It is not clear yet which candidate vaccine will be given and how many people will be vaccinated.

At least two experimental vaccines, one from Sinovac Biotech Ltd and the other from China National Biotec Group, have been approved for emergency use in China.

No vaccine has yet passed final, large-scale trials to prove it is effective enough to protect people from contracting the virus that has led to over 860,000 deaths globally.

Tags : #China #SouthAsia #Asia #COVID-19 #Vaccine #Experimentalvaccine #Workers #Aviation

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Achieving Healthier Lifestyles: Understanding India's New Dietary GuidelinesMay 11, 2024
The Link Between Childhood Sleep and Adult Psychosis: A Critical AnalysisMay 11, 2024
Uncovering Immunization Gaps: Insights into Measles Vaccination Challenges in IndiaMay 11, 2024
Unlocking New Horizons: Gene Therapies for Hearing Loss and BlindnessMay 10, 2024
Kerala Health Alert: West Nile Fever Cases Confirmed in Thrissur, Malappuram, and KozhikodeMay 10, 2024
Managing Health in the Heat: Demand for Medications Surges in IndiaMay 10, 2024
Sudhamukti Ayurvedic Medicine by OJSP: A New Era in Diabetes ManagementMay 10, 2024
The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
Reducing Stigma, One Story at a Time: Media's Role in Mental HealthMay 07, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024